Table 1 Baseline characteristics of the 55 study participants
From: Neurologic outcome of VZV encephalitis one year after ICU admission: a multicenter cohort study
Variable | Patients n = 55 |
|---|---|
Age, years, median [IQR] | 53 [36–66] |
Male sex, n (%) | 29 (53%) |
Underlying immunosuppression, n (%) | 43 (78%) |
Steroids | 20 (36%) |
Solid organ transplant | 12 (22%) |
HIV | 11 (20%) |
Hematological malignancy | 11 (20%) |
Solid neoplasm | 3 (5%) |
Other causes of immunosuppressiona | 8 (15%) |
Reason for ICU admission, n (%) | |
Confusion | 22 (40%) |
Coma | 20 (36%) |
Status epilepticus | 10 (18%) |
Neurologic deficits | 3 (5%) |
VZV-related organ involvement, n (%) | |
Skin rash | 37 (67%) |
Pneumonia | 11 (20%) |
Hepatitis | 11 (20%) |
Neurological symptoms | 55 (100%) |
Confusion | 27 (49%) |
Coma | 20 (36%) |
Seizures | 18 (33%) |
Headaches | 18 (33%) |
Neurologic deficits | 17 (31%) |
Ataxia | 3 (5%) |
Time from the onset of neurological symptoms to ICU admission, days, median [IQR] | 1 [0–3] |
Clinical parameters at ICU admission, median [IQR] | |
Temperature | 38.5 [37.3–39.3] |
SOFA | 6 [4–9] |
GCS | 12 [7–14] |
Cerebrospinal fluid examination, median [IQR] | 55 (100%) |
Leukocytes, /mm3 | 68 [13–129] |
Lymphocytes, /mm3 | 70 [27–95] |
Neutrophils, /mm3 | 25 [3–40] |
Protein, g/L | 1.37 [0.77–3.67] |
Glucose, mmol/L | 3.8 [2.6–5.0] |
Positive VZV PCR, n (%) | 55 (100%) |
Brain CT-scan, n (%) | 33 (60%) |
Abnormal findings | 10 (30%) |
Brain MRI, n (%) | 30 (55%) |
Abnormal findings | 21 (70%) |
EEG, n (%) | 24 (44%) |
Abnormal findings | 18 (75%) |